Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SOTALOL HCI
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $69.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 26, 2020
Details:
This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alprostadil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: $98.0 million Upfront Cash: $84.0 million
Deal Type: Agreement March 06, 2020
Details:
The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
